Get the Stockscreener App
0.9289
3.14%
-0.0301
After Hours:
.94
0.0111
+1.19%
Enlivex Therapeutics Ltd stock is traded at $0.9289, with a volume of 922.08K.
It is down -3.14% in the last 24 hours and down -8.93% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$0.959
Open:
$0.99
24h Volume:
922.08K
Relative Volume:
0.26
Market Cap:
$219.49M
Revenue:
-
Net Income/Loss:
$-14.33M
P/E Ratio:
-1.4074
EPS:
-0.66
Net Cash Flow:
$-13.21M
1W Performance:
-23.23%
1M Performance:
-8.93%
6M Performance:
-1.18%
1Y Performance:
-23.23%
1-Day Range:
$0.90
$0.9998
1-Week Range:
$0.90
$1.24
52-Week Range:
$0.8313
$2.10
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare ENLV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
0.9289 | 226.60M | 0 | -14.33M | -13.21M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
What drives Enlivex Therapeutics Ltd stock pricePrice Support Zones & Rapid Capital Gain - earlytimes.in
Enlivex: A Necessary UpdateThis Is No Longer The Company We Covered In 2022 (NASDAQ:ENLV) - Seeking Alpha
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial
An analyst sees good growth prospects for Enlivex Therapeutics Ltd (ENLV) - setenews.com
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial
Enlivex Therapeutics Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Enlivex Announces Fireside Chat on RAIN Token and Allocetra Development - TipRanks
Enlivex Therapeutics Ltd. Announces Virtual Fireside Chat to Discuss Digital Asset Strategy and Clinical Development Plans - Quiver Quantitative
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development - 富途牛牛
How Enlivex Therapeutics Ltd. stock reacts to oil pricesTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
Enlivex announces fireside chat on RAIN token and Allocetra development - MSN
Can Enlivex Therapeutics Ltd. stock sustain revenue growth2025 Stock Rankings & AI Enhanced Execution Alerts - Newser
Is Enlivex Therapeutics Ltd. stock a safe haven asset2025 Stock Rankings & Weekly Setup with ROI Potential - Newser
Enlivex Therapeutics (ENLV) Stock Analysis Report | Financials & Insights - Benzinga
What analysts say about Enlivex Therapeutics Ltd stockTechnical Breakout Signals & Rapid Profit Growth - earlytimes.in
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
Panic Selling: What margin trends mean for Enlivex Therapeutics Ltd. stock2025 Key Lessons & Verified Chart Pattern Signals - moha.gov.vn
Enlivex Therapeutics Announces Closing of Previously Announced $212,000,000 Private Placement - marketscreener.com
Surprises Report: What margin trends mean for Enlivex Therapeutics Ltd. stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - moha.gov.vn
Enlivex Therapeutics Ltd (ENLV): What Does Valuation Ratios Tell Us? - fostersleader.com
Working capital per share of Enlivex Therapeutics Ltd. – FWB:1BT - TradingView
Enlivex Therapeutics (ENLV) Finalizes $212M Private Investment - GuruFocus
Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy - TipRanks
Best Penny Stocks to Buy Now, According to ChatGPT - Blockonomi
Enlivex Therapeutics Adopts First RAIN Digital Asset Treasury Strategy and Welcomes Former Italian Prime Minister Matteo Renzi to Board of Directors | ENLV Stock News - Quiver Quantitative
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement - The Manila Times
[6-K] Enlivex Therapeutics Ltd. Current Report (Foreign Issuer) | ENLV SEC FilingForm 6-K - Stock Titan
Enlivex Therapeutics Ltd. Announces Resignation of Andrew Singer from Board of Directors - marketscreener.com
Enlivex Therapeutics (Nasdaq: ENLV) closes $212M raise, adds Matteo Renzi to board - Stock Titan
Best Penny Stocks To Buy Now, ChatGPT’s Top Picks - CoinCentral
Enlivex Therapeutics Ltd. (ENLV) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Enlivex Therapeutics (NASDAQ:ENLV) Rating Lowered to “Hold” at D Boral Capital - Defense World
Nasdaq penny stock plans $212M RAIN token play with ex-Italian PM onboard - MSN
Enlivex Reports Positive Six-Month Data for Knee Osteoarthritis Trial - MSN
Enlivex Completes Private Placement to Fund Digital Asset Strategy - MSN
There is no doubt that Enlivex Therapeutics Ltd (ENLV) ticks all the boxes. - setenews.com
Enlivex’s allogeneic cell therapy benefit continues at six months - Clinical Trials Arena
Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi - marketscreener.com
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors - Lelezard
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board - AI Magazine
Rain Token Strategy: How Enlivex is Pioneering Blockchain Treasury Innovation - OKX
RAIN surge over 100% as Enlivex plans a $212 million treasury for the token - FXStreet
Enlivex Therapeutics Ltd. announced that it has received $9.5 million in funding - marketscreener.com
Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120% - Coinspeaker
Enlivex Therapeutics’ Pharmaceuticals Breakthrough - StocksToTrade
Enlivex Therapeutics Ltd. (ENLV) Stock: Soars 50% Following Strong 6-Month Allocetra™ Knee OA Data - parameter.io
ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board - Stocktwits
Enlivex Therapeutics Ltd. announced that it expects to receive $9.5 million in funding - marketscreener.com
Enlivex, with Matteo Renzi on Board, Launches First RAIN-Backed Treasury to Power Israeli Biotech via Prediction Markets - https://debuglies.com
Enlivex Therapeutics files for offering of up to $299.6 mln of ordinary shares - MarketScreener
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):